Evolocumab: A Review in Hyperlipidemia.

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Hypercholesterolemia and familial hypercholesterolemia are significant risk factors for cardiovascular disease.
• Current lipid-lowering therapies, including statins, may not be sufficient for all patients.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a novel therapeutic class.

Purpose of the Study:

• To evaluate the efficacy and tolerability of evolocumab in reducing low-density lipoprotein cholesterol (LDL-C) levels.
• To assess evolocumab's effectiveness across various patient populations, including those with primary hypercholesterolemia, mixed dyslipidemia, and familial hypercholesterolemia.
• To determine evolocumab's role as an adjunct or alternative therapy to statins.

Main Methods:

• Phase III clinical trials involving patients with primary hypercholesterolemia, mixed dyslipidemia, and familial hypercholesterolemia.
• Subcutaneous administration of evolocumab at 140 mg every 2 weeks or 420 mg once monthly.
• Comparison of evolocumab's efficacy against placebo and/or ezetimibe, both as monotherapy and in combination with statins.

Main Results:

• Evolocumab significantly reduced LDL-C levels compared to placebo (treatment difference -54.8 to -76.3%) and ezetimibe (treatment difference -36.9 to -47.2%) in patients with primary hypercholesterolemia or mixed dyslipidemia.
• Significant LDL-C reduction (≈30% vs. placebo) was observed in homozygous familial hypercholesterolemia patients when evolocumab was added to statins.
• Evolocumab demonstrated sustained efficacy and good tolerability in longer-term follow-up.

Conclusions:

• Subcutaneous evolocumab is an effective treatment for primary hypercholesterolemia, mixed dyslipidemia, and homozygous familial hypercholesterolemia.
• Evolocumab provides a valuable therapeutic option for patients unable to achieve LDL-C goals with statins or who are statin-intolerant.
• The PCSK9 inhibitor offers a new strategy for managing dyslipidemia and reducing cardiovascular risk.